Spyros Triantos

Spyros Triantos

Johnson & Johnson Co. - New Jersey / United States
Medical and Health Sciences / Medical Oncology
AD Scientific Index ID: 5379118
-
person_outline Spyros Triantos's MOST POPULAR ARTICLES
1-) Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinomaY Loriot, N Matsubara, SH Park, RA Huddart, EF Burgess, N Houede, ...New England Journal of Medicine 389 (21), 1961-1971, 2023572023
2-) Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 studyS Pant, M Schuler, G Iyer, O Witt, T Doi, S Qin, J Tabernero, DA Reardon, ...The Lancet Oncology 24 (8), 925-935, 2023522023
3-) Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast …Y Loriot, N Matsubara, SH Park, RA Huddart, EF Burgess, N Houede, ...Journal of Clinical Oncology, 2023402023
4-) A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancerBJ Monk, TJ Herzog, G Wang, S Triantos, S Maul, R Knoblauch, ...Gynecologic oncology 156 (3), 535-544, 2020422020
5-) Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trialAO Siefker-Radtke, N Matsubara, SH Park, RA Huddart, EF Burgess, ...Annals of Oncology 35 (1), 107-117, 2024382024